Market News & Trends
Mural Oncology Announces Agreement to be Acquired by XRA 5 Corp.
Mural Oncology plc and XOMA Royalty Corporation recently announced they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed…
Trethera Awarded $3-Million NIH Grant to Advance First-In-Class Drug for the Treatment of Lupus
Trethera Corporation recently announced it has been awarded a $3-million Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). The award…
BioMed X & Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
BioMed X recently announced the launch of a new collaboration with Novo Nordisk, a leading global healthcare company headquartered in Denmark. This partnership aims to…
Memo Therapeutics Publishes Phase 1 Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical & Translational Science
Memo Therapeutics AG has published Phase 1 clinical data in Clinical and Translational Science, highlighting the safety, tolerability, and pharmacokinetics (PK) of its lead clinical…
Rein Therapeutics Wins Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the company to initiate its Phase 2 RENEW clinical trial…
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
ALX Oncology Holdings Inc. recently announced the first patient has been dosed in the company’s Phase 1 clinical trial for ALX2004, a potential best- and…
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
BiomX Inc. recently announced the US FDA has placed a clinical hold on the Phase 2b trial of BX004 for the treatment of patients with…
Invivyd Announces Continued Neutralizing Activity of PEMGARDA & VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG
Invivyd, Inc. recently announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA (pemivibart) against the currently dominant and growing XFG variant of SARS-CoV-2.…
Upperton Pharma Solutions Awarded VaxHub Sustainable Grant to Advance Oral Vaccine Delivery in Partnership With the University of Oxford’s Pandemic Sciences Institute
Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform…
Ascentage Pharma Announces Global Registrational Phase 3 Study of Lisaftoclax for First-line Treatment of Patients With Higher-Risk Myelodysplastic Syndrome Cleared by FDA & EMA
Ascentage Pharma recently announced it has received clearance by the US FDA and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global…
Valneva’s Chikungunya Vaccine Now Authorized in Canada for Individuals Aged 12 & Older
Valneva SE recently announced Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ, for the prevention of disease caused by the chikungunya virus…
Traws Pharma Receives Approval to Proceed With Phase 2 COVID Studies With Ratutrelvir
Traws Pharma, Inc. recently announced receipt from the Human Research Ethics Committee (HREC) of approval to proceed with a Phase 2 study to evaluate ratutrelvir, a…
Reunion Neuroscience Announces Positive Topline Results From Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
Reunion Neuroscience, Inc. recently announced positive topline results from its RECONNECT Phase 2 clinical trial evaluating RE104 in adult female patients with moderate-to-severe postpartum depression…
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate
Opus Genetics recently announced the US FDA has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1…
Halda Therapeutics Receives FDA Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer Treatment
Halda Therapeutics recently announced the US FDA granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with metastatic…
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
Tiziana Life Sciences, Ltd. recently announced the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients…
Fifty 1 Labs & The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study
Fifty1 AI Labs, Inc. recently announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a decade's worth…
Superluminal Medicines Announces Collaboration With Eli Lilly to Advance Small Molecule Therapeutics for Cardiometabolic Diseases & Obesity
Superluminal Medicines recently announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and…
Veranova’s Devens Site Successfully Passes FDA Inspection With Zero Observations
Veranova recently announced that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the Food and Drug Administration…
Colorcon Ventures Invests in Phytolon to Advance the Future of Natural Colorants
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Phytolon, a startup company offering natural food coloring via precision fermentation of modified…
